Cardiometabolic Phenotyping in Primary Care: A Comprehensive Review

Abstract

Cardiometabolic phenotyping represents a pivotal evolution in the management of cardiometabolic diseases within primary care settings. By integrating clinical, biochemical, and imaging assessments, phenotyping enables healthcare professionals to identify disease subtypes, stratify risk, and tailor interventions. This review synthesizes the latest evidence, highlighting epidemiological trends, pathophysiological mechanisms, risk factors, clinical presentations, diagnostic approaches, management strategies, and emerging therapies. It underscores the practical and guideline-based implications of phenotyping, providing primary care physicians with actionable insights to improve patient outcomes in the era of precision medicine.

Introduction

Cardiometabolic diseases, encompassing conditions such as type 2 diabetes mellitus, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease, remain the leading causes of morbidity and mortality globally. Primary care is the first point of contact for most patients, positioning it uniquely to drive early identification and intervention. Cardiometabolic phenotyping, which entails systematic classification of patients based on shared clinical and biological traits, has emerged as a cornerstone for precision prevention and management. This article explores the scientific and clinical framework for phenotyping in primary care, aiming to inform and optimize practice for healthcare professionals.

Epidemiology / Disease Burden

Cardiometabolic disorders have reached pandemic proportions, with the World Health Organization estimating over 500 million adults affected by diabetes and more than 1 billion living with hypertension. The overlap of metabolic syndrome, marked by central obesity, insulin resistance, dyslipidemia, and hypertension, amplifies cardiovascular risk exponentially. In primary care cohorts, multimorbidity is common, and traditional risk assessment tools may underestimate true disease burden. Phenotyping provides nuanced risk stratification, revealing subgroups such as those with metabolically healthy obesity or lean individuals with insulin resistance who may otherwise be overlooked by standard algorithms.

Pathophysiology

The pathophysiology underlying cardiometabolic diseases is heterogeneous and multifactorial. Central to these conditions is a complex interplay between genetic susceptibility, visceral adiposity, chronic low-grade inflammation, dysregulated adipokine production, endothelial dysfunction, and aberrant lipid and glucose metabolism. Advanced phenotyping methods, including genomics, proteomics, and metabolomics, have elucidated distinct molecular pathways that drive disease heterogeneity. For example, some phenotypes exhibit pronounced hepatic insulin resistance, while others are characterized by adipose tissue dysfunction or exaggerated sympathetic activity. Recognizing these mechanistic differences is essential for targeted therapy.

Risk Factors

Traditional risk factors such as age, sex, family history, sedentary lifestyle, unhealthy diet, smoking, and excess body weight are well established. However, phenotyping has refined risk assessment by highlighting the importance of factors like ectopic fat deposition (e.g., hepatic steatosis, epicardial fat), specific lipid abnormalities (e.g., high triglycerides, low HDL-C), markers of subclinical inflammation (e.g., hs-CRP, interleukin-6), and genetic variants. Social determinants of health, including socioeconomic status and psychosocial stress, further modulate risk profiles and should be integrated into comprehensive phenotyping models.

Clinical Features

Cardiometabolic phenotypes manifest with a spectrum of clinical features, ranging from asymptomatic metabolic disturbances to overt cardiovascular events. Common presentations include central obesity, hypertension, impaired glucose tolerance, dyslipidemia, and microvascular complications (e.g., retinopathy, nephropathy). Some phenotypes, such as those with metabolically healthy obesity, may exhibit minimal metabolic derangements despite increased adiposity, whereas others (e.g., TOFI thin outside, fat inside) present with significant metabolic risk despite normal BMI. Recognizing subtle clinical cues is critical for early diagnosis and intervention.

Diagnosis

Diagnostic evaluation in primary care relies on a combination of clinical assessment, anthropometric measurements (e.g., waist circumference, BMI), laboratory investigations (fasting glucose, HbA1c, lipid profile, liver function tests), and, increasingly, imaging modalities (e.g., ultrasound for hepatic steatosis, coronary artery calcium scoring). Novel biomarkers such as adiponectin, leptin, and emerging metabolomic signatures are being investigated for their utility in refining phenotypes. Risk calculators (e.g., QRISK3, ASCVD risk estimator) remain useful but may need adjustment or supplementation for specific phenotypes. Regular screening and phenotypic reassessment are recommended to capture disease evolution over time.

Treatment & Management

Management strategies are increasingly tailored to individual phenotypes. Lifestyle modification remains foundational, with evidence supporting structured exercise, dietary optimization (Mediterranean, DASH, or low-carbohydrate diets), smoking cessation, and weight reduction. Pharmacotherapy is guided by phenotype-specific risk: for example, SGLT2 inhibitors and GLP-1 receptor agonists are prioritized in patients with obesity and high cardiovascular risk, while statins are essential for those with atherogenic dyslipidemia. Multimorbidity management requires integrated, multidisciplinary approaches, often involving coordination with endocrinology, cardiology, and nutrition specialists. Patient education and shared decision-making are crucial to optimize adherence and outcomes.

Recent Advances / Emerging Therapies

Recent advances in cardiometabolic phenotyping include the use of artificial intelligence to analyze electronic health records and imaging data, the application of polygenic risk scores for early risk identification, and the development of novel biomarkers to differentiate phenotypes. Emerging therapies such as dual agonists targeting both GLP-1 and GIP receptors, PCSK9 inhibitors for lipid lowering, and anti-inflammatory agents (e.g., IL-1β inhibitors) are showing promise for specific subgroups. Digital health interventions and remote monitoring are enhancing phenotyping capabilities and patient engagement in primary care settings.

Guideline Recommendations

Major guidelines including those from the American Diabetes Association (ADA), European Society of Cardiology (ESC), and American Heart Association (AHA) increasingly endorse precision medicine approaches. They recommend comprehensive risk assessment, integration of phenotypic data, and individualized management plans. Regular screening for metabolic syndrome components, aggressive risk factor modification, and periodic reassessment of phenotypes are emphasized. Guidelines also highlight the importance of addressing health disparities and incorporating social determinants into risk stratification.

Conclusion

Cardiometabolic phenotyping is redefining disease management in primary care by enabling more accurate risk stratification, personalized therapy, and improved outcomes. As evidence and technology advance, primary care practitioners must stay abreast of evolving phenotyping methods and therapeutic options. Integration of comprehensive phenotyping into routine practice promises to transform prevention, diagnosis, and management of cardiometabolic diseases, aligning with the goals of precision medicine and population health.